Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online)

A REVIEW OF DRUG - INDUCED

RICHA DODIA AND SUSMITA SAHOO

NATUBHAI V. PATEL COLLEGE OF PURE AND

APPLIED SCIENCES, CHARUTAR VIDYA MANDAL SINCE 2010 UNIVERSITY, VALLABH VIDYANAGAR, ANAND- 388315, GUJARAT, INDIA.

NAAS Rating Corresponding author’s e-mail: [email protected] 2012:1.3; 2013-16: 2.69 2017-2020: 3.98

ABSTRACT:

IMPACT FACTOR Drug-induced diabetes is outlined because of the new development of 2019-20: 2.40; 2021:1.09 a hyperglycaemic state that meets the definition of diabetes which is

thanks to the consumption of a drug. This medication area unit

IPI Value classified in step with the mechanism by that they induce diabetes. The 1.92 primary cluster interferes with resistance and insulin Received on: deficiency, the second interferes with insulin deficiency, the third 25th March 2021 cluster interferes with insulin resistance, and the fourth cluster Revised on: 1st April 2021 interferes with medication that destroys beta cells. Accepted on: 10th April 2021 KEYWORDS: Drug-induced diabetes, Insulin resistance, Insulin Published on: deficiency, Drugs that destroy beta Insulin resistance. 1st June 2021 INTRODUCTION: Volume No. Drug-induced diabetes is the utilization of a selected medication has Online & Print 135-136 (2021) causes the event of diabetes [1]. In some cases, the event of diabetes could also be reversible if the utilization of the medication is Page No. interrupted, however, in different cases, drug-induced diabetes could 01 to 08 Life Sciences Leaflets also be permanent. They act by increasing insulin resistance by is an international open affecting insulin, or both [2]. For convenience, these agents could also access print & e be divided into wide used medication that is weakly diabetic and journal, peer reviewed, worldwide abstract medicines used for special indications that have a lot of powerful listed, published every diabetic properties [3]. month with ISSN, RNI Free- membership, Insulin resistance and insulin deficiency downloads and access. https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 1

Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online)

The use of Glucocorticoids is for the treatment of inflammatory things and autoimmune diseases [4]. Diabetes and polygenic disorder are adverse effects of Glucocorticoids, diabetes-induced through Glucocorticoids is conjointly called diabetes, and even hyperglycaemic hyperosmolar nonketotic coma secondary to corticosteroid use has been reported [5].Mechanism of -induced is reduced insulin sensitivity. excite internal organ hepatic production and stop peripheral aldohexose uptake in muscle and fatty tissue, beyond insulin resistance. More modern studies have urged injurious effects of Glucocortids on pancreatic beta cells, foremost to reduced insulin production [6]. Initial recognition and applicable proactive management of Glucocorticoid-induced hyperglycemia measure are extremely urged. Patients on long-term glucocorticoid treatment and even patients on transient glucocorticoid treatment should be monitored at regular intervals [7]. Among lifestyle dealings, hypoglycaemic medicine with vital insulin sensitizer affects sensitizer indicated, additional oral hypoglycaemic medicine or insulin medical aid can be thought of as the second drug of choice. The initial consistent approach to glucocorticoid‐ induced diabetes is to minimize the glucocorticoid dose to the maximum amount possible. There are few studies of optimum medical treatment for glucocorticoid‐ induced diabetes [8]. Troglitazone has been given to progress postprandial glucose excursions that are the lower area beneath the glucose curve in an oral glucose tolerance test, decrease Glycated hemoglobin (A1C) test, decrease low‐ density lipoprotein, and increase insulin secretion in patients on chronic glucocorticoid,[9] It is suggested to cause side effects like weight gain, heart failure, and bone fractures, entirely of which can be additive to parallel side effects of glucocorticoids in America, the drug was removed from the shop in 2000. There are rare studies of the antidiabetic drug in glucocorticoid diabetes, and it's not ordinarily been suggested as various patients taking glucocorticoid have nephropathy or is also at risk of acidosis pathology, which constitutes contraindications to metformin [10]. The agreement is that blood sugar systematically over 200 mg/dL is related to glucocorticoid therapy should be treated with insulin [10]. Nicotinic acid Nicotinic acid conjointly referred to as niacin, could be a B vitamin prompt for dealing with dyslipidemia [11]. Nicotinic acid is used to treat dyslipidemia, is conversant to cause hyperglycemia that informed severe, though no such effect was discovered in an exceedingly trial in people with diabetes. Its analog, acipimox, doesn't have adverse effects on glycemic management in people with diabetes [12] within the latest analysis study investigates the consequences of niacin on plasma aldohexose, insulin, conjointly C-peptide stages in inactive nondiabetic biological time females, there was a big increase in mean glucose values following niacin medical aid [13]. Niacin-induced hyperglycemia is often associated with high doses, pre- https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 2

Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online) diabetes, or diabetes. Also, aging is among the danger factors for hyperglycemia throughout niacin medical aid [14]. The lipid‐ lowing drug, nicotinic acid, has long been acknowledged to lift blood sugar and hemoglobin A1C in patients with diabetes [15]. Statin Statins have an association through new-onset diabetes and conveys a Food and Drug Administration warning to this impact. Patients with baseline impaired glucose tolerance who started on statins had a statistically important hour of 1.32 for the event of diabetes [16]. Much statin‐ associated diabetes shows an odd ratio of about one.1 for the development of diabetes once taking statin for up to five years compared to placebo [17]. Hypotheses concerning the mechanism contain inhibition of insulin release through attenuated glucose communication within the beta-cell either or each multiplied beta-cell caspase-mediated cell death and diminished insulin sensitivity of muscle through the diminished expression of the glucose transporter, Glucose transporter type 4. Statins might induce insulin resistance through the suppression of adiponectin. There's proof that the magnitude of those effects varies from medicament to medicament, however, everyone has been related to a little increase in diabetes risk [17]. Insulin deficiency Calcineurin inhibitors Calcineurin inhibitor‐ associated diabetes capability is at first affected by the thought of changing from tacrolimus to cyclosporin A. There are few studies of medical aid for calcineurin inhibitor‐ associated diabetes and skilled opinion suggests that antidiabetic, Glucagon-Like Peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors ought to be explored[18]. Insulin medical aid ought to be introduced if further therapies don't management blood sugar. Calcineurin inhibitors are immunosuppressants that are typically used post‐ transplant to block nuclear factors of activated t cells induction of interleukin‐ 2 manufacture in lymphocytes [19]. Diazoxide Diazoxide is a non - diuretic benzothiadiazole by-product through potent vasodilator properties that was to treat hypertensive crises; it's currently occasionally used for this indication however is verificatory in cases of inoperable insulinoma and to treat profound hypoglycemia succeeding in antidiabetic overdose. The dose used for the treatment of patients through insulinoma ranges between 100 and 600 mg/day, repeatedly in separated doses [20]. Diazoxide could be a non- diuretic benzothiadiazole by-product that will increase the plasma concentration of glucose by decreasing insulin secretion through the gap of potassium or Adenosine Triphosphate channels

https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 3

Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online) within the membranes of exocrine gland beta cells and increasing the hepatic output of glucose [21]. Didanosine Didanosine antiretroviral reverse transcriptase substance nucleoside agonist can trigger pancreatitis in order the ready to patients and a few can have a consequent beta-cell injury. The didanosine-associated symptom has been postulated to decrease insulin secretion within the absence of pancreatitis [22]. Pentamidine Pentamidine seems to own a multiphasic impact on the beta-cell. Initially, the drug causes acute cytolysis and degranulation of beta-cells with the discharge of insulin and hypoglycemia. Later on, beta-cell destruction and impaired insulin release develop with the onset of hyperglycemia and even public diabetic ketoacidosis might occur at intervals a pair of – 6 months in up to 20 patients [23]. The anti-protozoal drug pentamidine has been used a lot in recent years as a result of its effectiveness in treating the infection with Pneumocystis carinii, as happens in patients with acquired immune deficiency. The drug will cause pancreatitis with low, normal, or raised blood glucose concentration [24] Patients with acquired immunodeficiency syndrome normally suffer from hypoglycemia throughout pentamidine treatment. In one survey of thirty-seven acquired immunodeficiency syndrome patients treated with the drug, nearly 1 / 4 developed hypoglycemia [25]. The symptom will follow hypoglycemia, and permanent diabetes will occur [26]. The mechanism of this biphasic response was investigated by [27], World Health Organization demonstrated that pentamidine initially stirred up insulin release from cultured insulinoma cells, then suppressed it and at last caused three-cell lysis. The consequences weren't apparent in vivo in a patient with a malignant insulinoma, however. The mechanism of beta-cell injury seems distinct from that of alloxan or streptozotocin [28]. Thiazide diuretics Thiazide diuretics in specific decrease insulin unleash and also the mechanism could also be related to hypokalemia that will increase the potassium gradient across the beta-cell membrane resulting in hyperpolarization. The proof is given that the hour for development of diabetes on a thiazide is 2.07 and the risk is the serum potassium with every 0.5 mEq/L decreases in serum metallic element will increase the danger of polygenic disease by 45% [29]. Gurwitz et al. [30] found that the danger for developing diabetes wasn't raised by treatment with thiazides alone, however, was raised with one antihypertensive agent. Gorden [31] had noted aldohexose intolerance and diminished humor hypoglycaemic agent in association with potassium-depleted staes, and Heldren et al. [32] recurrent the hyperglycemic clamp studies to point out that the wide https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 4

Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online) command of the defect might be corrected through careful potassium repletion. in a very randomized double-blind experiment, thiazide medical care raised plasma insulin and remittent index of insulin sensitivity ended a treatment period of 12-week [33]. Insulin resistance Megestrol Megestrol must cause quickly reversible hyperglycemia in some nonheritable immune deficiency syndrome patients through elevated insulin and c‐ peptide levels signifying insulin resistance rather than a hypoglycaemic agent body fluid defect [34]. Drugs that destroy beta cells Vacor Vacor is the rodenticide N-3-pyridyl methyl-N'-p-nitrophenyl urea. It is never been accustomed to treat human illness, however, there are some cases of accidental breakdown. The mortality in adults once the deliberate bodily process is up to twenty-fifth, and concerning 1/2 the survivors develop brittle diabetes at intervals hours to days of overdosage. Nicotinamide protects against Vacor-induced which are 3-cell harm, and this and also the structural similarity of Vacor to streptozotocin and alloxan imply an analogous mode of action [35]. Streptozotocin (streptozocin) Streptozotocin could be a nitrosourea compound, originally isolated from cultures of streptomyces chromogens, and currently factory-made synthetically. Experimental studies show that streptozotocin can cause 3-cell destruction, with loss of body fluid granules and aggregation of nuclear body substance, at intervals a number of hours on exposure [36]. The relative specificity for the exocrine gland could also be the result of the glucopyranose moiety interacting with the reputed 3-cell glucose receptor or glucose transporters. Streptozotocin enters the 3-cell and causes breaks within the deoxyribonucleic acid strands that cause activation of poly Adenosine diphosphate synthetase. The activation of this protein and consequent depletion of coenzyme in all probability inhibit proinsulin synthesis. Inhibitors of the synthetase can stop the fall in proinsulin synthesis [37].

CONCLUSIONS: Epidemiological studies and case reports have incontestable a hyperbolic rate of development of diabetes mellitus subsequent to taking numerous types of medication. This review explores this proof linking these medications and the development of diabetes and presents postulated mechanisms by that the medications may cause diabetes. Some medications are related to a reduction in production, some with a reduction in hormone sensitivity, and a few seem to be related to each reduction in insulin production and insulin sensitivity [38]. https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 5

Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online)

REFERENCES:

1. American Diabetes Association. (2009). Diagnosis and classification of diabetes mellitus. Diabetes care, 32(Supplement 1), S62-S67.

2. Ferner, R. E. (1992). 8 Drug-induced diabetes. Baillière's clinical endocrinology and metabolism, 6(4), 849-866.

3. https://www.diabetes.co.uk/author/editor/

4. Yang, J. Y., Cui, X. L., & He, X. J. (1995). Non-ketotic hyperosmolar coma complicating steroid treatment in childhood nephrosis. Pediatric Nephrology, 9(5), 621-622.

5. Jensen, K., Steinthorsdottir, K. J., & Brandt, B. (2013). In-hospital cardiac arrest due to unobserved steroid-induced hyperglycaemic hyperosmolar syndrome. Ugeskrift for laeger, 175(15), 1044-1045.

6. Delaunay, F., Khan, A., Cintra, A., Davani, B., Ling, Z. C., Andersson, A., ... & Okret, S. (1997). Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. The Journal of clinical investigation, 100(8), 2094-2098.

7. Gurwitz, J. H., Bohn, R. L., Glynn, R. J., Monane, M., Mogun, H., & Avorn, J. (1994). Glucocorticoids and the risk for initiation of hypoglycemic therapy. Archives of internal medicine, 154(1), 97-101.

8. Van Raalte, D. H., & Diamant, M. (2014). Steroid diabetes: from mechanism to treatment. Neth J Med, 72(2), 62-72.

9. Willi, S. M., Kennedy, A., Brant, B. P., Wallace, P., Rogers, N. L., & Garvey, W. T. (2002). Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes research and clinical practice, 58(2), 87-96.

10. Perez, A., Jansen‐Chaparro, S., Saigi, I., Bernal‐Lopez, M. R., Miñambres, I., & Gomez‐Huelgas, R. (2014). Glucocorticoid‐induced hyperglycemia. Journal of diabetes, 6(1), 9-20.

11. Pieper, J. A. (2003). Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. American journal of health-system pharmacy, 60(suppl_2), S9-S14.

12. Dean, J. D., McCarthy, S., Betteridge, D. J., Whately‐Smith, C., Powell, J., & Owens, D. R. (1992). The effect of acipimox in patients with and persistent hyperlipidaemia. Diabetic medicine, 9(7), 611-615.

13. Koh, Y., Bidstrup, H., & Nichols, D. L. (2014). Niacin increased glucose, insulin, and C- peptide levels in sedentary nondiabetic postmenopausal women. International journal of women's health, 6, 913.

14. Kahn, S. E., Beard, J. C., Schwartz, M. W., Ward, W. K., Ding, H. L., Bergman, R. N., ... & Porte, D. (1989). Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes, 38(5), 562-568.

15. Grundy, S. M., Vega, G. L., McGovern, M. E., Tulloch, B. R., Kendall, D. M., Fitz- Patrick, D., ... & Sheehan, J. P. (2002). Efficacy, safety, and tolerability of once-daily https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 6

Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online)

niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Archives of Internal Medicine, 162(14), 1568-1576.

16. Shen, Lan, Bimal R. Shah, Eric M. Reyes, Laine Thomas, Daniel Wojdyla, Peter Diem, Lawrence A. Leiter et al. "Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study." Bmj 347 (2013).

17. Navarese, E. P., Szczesniak, A., Kolodziejczak, M., Gorny, B., Kubica, J., & Suryapranata, H. (2014). Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy?. American Journal of Cardiovascular Drugs, 14(2), 79-87.

18. Sharif, A., & Cohney, S. (2016). Post-transplantation diabetes—state of the art. The Lancet Diabetes & Endocrinology, 4(4), 337-349.

19. Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003). Diabetes mellitus after kidney transplantation in the United States. American Journal of Transplantation, 3(2), 178-185.

20. Gill, G. V., Rauf, O., & MacFarlane, I. A. (1997). Diazoxide treatment for insulinoma: a national UK survey. Postgraduate Medical Journal, 73(864), 640-641.

21. Mariot, P., Gilon, P., Nenquin, M., & Henquin, J. C. (1998). Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells. Diabetes, 47(3), 365-373.

22. Munshi, M. N., Martin, R. E., & Fonseca, V. A. (1994). Hyperosmolar nonketotic diabetic syndrome following treatment of human immunodeficiency virus infection with didanosine. Diabetes Care, 17(4), 316-317.

23. Rajmohan, L., & Mohan, V. (1997). Drug induced diabetes mellitus. japi, 45, 876-9.

24. SALMERON, S., PETITPRETZ, P., KATLAMA, C., HERVE, P., BRIVET, F., SIMONNEAU, G., ... & RéGNIER, B. E. R. N. A. R. D. (1986). Pentamidine and pancreatitis. Annals of Internal Medicine, 105(1), 140-141.

25. Stahl‐Bayliss, C. M., Kalman, C. M., & Laskin, O. L. (1986). Pentamidine‐induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clinical Pharmacology & Therapeutics, 39(3), 271-275.

26. Shen, M., Orwoll, E. S., Conte Jr, J. E., & Prince, M. J. (1989). Pentamidine-induced pancreatic beta-cell dysfunction. The American journal of medicine, 86(6), 726-728.

27. Osei, K., Falko, J. M., Nelson, K. P., & Stephens, R. (1984). Diabetogenic effect of pentamidine: in vitro and in vivo studies in a patient with malignant insulinoma. The American journal of medicine, 77(1), 41-46.

28. Boillot D, Veld P, Sai Pet al (1985) functional and morphological modifications induced in rat islets by pentamidine and other diamidines in vitro. DiabetoIogia 28: 359-364

29. Shafi, T., Appel, L. J., Miller III, E. R., Klag, M. J., & Parekh, R. S. (2008). Changes in serum potassium mediate thiazide-induced diabetes. Hypertension, 52(6), 1022-1029. https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 7

Life Sciences Leaflets FREE DOWNLOAD ISSN 2277-4297(Print) 0976–1098(Online)

30. Gurwitz, J. H., Bohn, R. L., Glynn, R. J., Monane, M., Mogun, H., & Avorn, J. (1993). Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Annals of internal medicine, 118(4), 273-278.

31. Gorden, P. (1973). Glucose intolerance with hypokalemia: Failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia. Diabetes, 22(7), 544-551.

32. Helderman, J. H., Elahi, D., Andersen, D. K., Raizes, G. S., Tobin, J. D., Shocken, D., & Andres, R. (1986). Prevention of the Glucose Intolerance of Thiazide Diuretics by Maintenance of Body-Potassium. In Diuretika III (pp. 98-109). Springer, Berlin, Heidelberg.

33. Plavinik, F. L., Rodrigues, C. I., Zanella, M. T., & Ribeiro, A. B. (1992). Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension, 19(2_supplement), II26.

34. Jain, P., Girardi, L. S., Sherman, L., Berelowicz, M., & Smith, L. G. (1996). Insulin resistance and development of diabetes mellitus associated with therapy. Postgraduate medical journal, 72(848), 365-367.

35. Gallanosa, A. G., Spyker, D. A., & Curnow, R. T. (1981). Diabetes mellitus associated with autonomic and peripheral neuropathy after Vacor rodenticide poisoning: a review. Clinical toxicology, 18(4), 441-449.

36. Lazarus, S. S., SS, L., & SH, S. (1972). Serial morphologic changes in rabbit pancreatic islet cells after streptozotocin.

37. Uchigata, Y., Yamamoto, H., Nagai, H., & Okamoto, H. (1983). Effect of poly (ADP- ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis. Diabetes, 32(4), 316-318.

38. Repaske, D. R. (2016). Medication‐induced diabetes mellitus. Pediatric diabetes, 17(6), 392-397.

https://lifesciencesleaflets.petsd.org/ PEER-REVIEWED Page | 8